To the Editor: We write to encourage policy debate over newborn screening for congenital adrenal hyperplasia (CAH). Classical CAH is a severe, life-threatening disease affecting about one in 15 000 liveborn infants in Australia.1 An inexpensive screening test for newborns is available, but this test is not included in the current newborn screening program in Australia.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- Garry L Warne1,2
- Katrina L Armstrong3
- Thomas A Faunce4
- Bridget M Wilcken5
- Avihu Boneh6
- Elizabeth Geelhoed7
- Maria E Craig5,2
- 1 Royal Children’s Hospital, Melbourne, VIC.
- 2 Australasian Paediatric Endocrine Group, Sydney, NSW.
- 3 CLAN (Caring and Living As Neighbours), Sydney, NSW.
- 4 Australian National University, Canberra, ACT.
- 5 Children’s Hospital at Westmead, Sydney, NSW.
- 6 Murdoch Childrens Research Institute, Melbourne, VIC.
- 7 University of Western Australia, Perth, WA.
Correspondence: m.craig@unsw.edu.au
Online responses are no longer available. Please refer to our instructions for authors page for more information.